Projects per year
Abstract
Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested − inhibition of angiogenesis − has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g vascular endothelial growth factor) are strongly associated with disease progression. One of the reasons for these outcomes may be our poor understanding of the biology of angiogenesis in prostate cancer (and probably other cancers as well) resulting in inhibition of both detrimental and favourable molecules. We discuss here novel targeted and more specific approaches to inhibit angiogenesis in prostate cancer as well as a completely new therapeutic modality to do this − modulation of alternative splicing − that may be applicable to other molecules/biological processes as well.
Original language | English |
---|---|
Pages (from-to) | 276-281 |
Number of pages | 6 |
Journal | Pharmacological Research |
Volume | 107 |
Early online date | 16 Mar 2016 |
DOIs | |
Publication status | Published - May 2016 |
Keywords
- Prostate cancer
- Angiogenesis
- Alternative splicing
- Novel therapeutics
Fingerprint
Dive into the research topics of 'SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing'. Together they form a unique fingerprint.Projects
- 2 Finished
-
Anti-angiogenic compounds based on modulation of VEGF splicing
Oltean, S. (Principal Investigator)
1/10/16 → 1/02/17
Project: Research
-
mRNA splicing control in diabetes: a novel therapeutic strategy for the treatment of diabetic nephropathy
Oltean, S. (Principal Investigator)
1/08/15 → 31/07/18
Project: Research